Citius Pharmaceuticals Inc (CTXR NASDAQ) stock market data APIs
$0.7789
0(0%)
as of December 31, 2025
Try our APIs with
free plan!
Citius Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Prev. Close
0.7789
Open
0.7819
High
0.8023
Low
0.7648
52 wk Range
0.63-4.51
Market Cap
16 257 K
Shares Outstanding
20 763 K
EPS
-0.11
Beta
1.509
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Citius Pharmaceuticals Inc data using free add-ons & libraries
Get Citius Pharmaceuticals Inc Fundamental Data
Citius Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -38 524 176
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-24
- EPS/Forecast: -0.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Citius Pharmaceuticals Inc News
New
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: UiPath Inc.(NYSE:PATH) shares gained in extended tradin...
Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years
(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or...
Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading
(RTTNews) - Biotech and healthcare stocks saw notable activity in Friday's after-hours trading session, with several names posting sharp moves on the back of corporate updates and investor anticipatio...
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR CRANFORD, N.J., Oct. 20, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR),...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
